Published in Clin J Am Soc Nephrol on March 12, 2008
Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol (2010) 2.66
Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol (2009) 1.18
Sensitized renal transplant recipients: current protocols and future directions. Nat Rev Nephrol (2010) 0.94
Acute rejection associated with donor-specific anti-MICA antibody in a highly sensitized pediatric renal transplant recipient. Pediatr Transplant (2010) 0.82
Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates. Clin Transplant (2012) 0.82
Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013. Pediatr Nephrol (2013) 0.81
The specificity of acute and chronic microvascular alterations in renal allografts. Clin Transplant (2013) 0.79
Antibody-incompatible kidney transplantation in 2015 and beyond. Nephrol Dial Transplant (2014) 0.77
Early and Sustained Reduction in Donor-Specific Antibodies in Desensitized Living Donor Kidney Transplant Recipients: A 3-Year Prospective Study. Transplant Direct (2016) 0.76
Laparoscopic splenectomy to salvage renal transplants from severe acute antibody-mediated rejection. Case Rep Transplant (2012) 0.75
A Comparison of Two Types of Rabbit Antithymocyte Globulin Induction Therapy in Immunological High-Risk Kidney Recipients: A Prospective Randomized Control Study. PLoS One (2016) 0.75
Management of sensitized pediatric patients prior to renal transplantation. Pediatr Nephrol (2016) 0.75
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med (2006) 4.79
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant (2003) 4.54
A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant (2006) 2.37
Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant (2007) 2.28
Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant (2002) 2.01
Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation (2000) 1.85
Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant (2003) 1.58
A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation (2000) 1.39
Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant (2004) 1.38
Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant (2003) 1.29
The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant (2007) 1.19
Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant (2006) 1.12
Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation (2003) 1.10
Sensitization after kidney transplantation. Clin J Am Soc Nephrol (2006) 1.09
Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation (2003) 1.08
Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: a pilot study. Am J Transplant (2007) 1.06
Evolution of HLA antibody detection: technology emulating biology. Immunol Res (2004) 1.05
Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation (2004) 0.98
Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation (2004) 0.96
B-cell activity of polyclonal antithymocyte globulins. Transplantation (2006) 0.93
Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant (2006) 0.92
Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. Transplantation (2003) 0.92
Intravenous immunoglobulin and thymoglobulin induction treatment in immunologically high-risk kidney transplant recipients. Transplantation (2005) 0.85
Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients. Transplantation (2003) 0.85
Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients. Hum Immunol (2005) 0.83
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol (2003) 11.94
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol (2005) 7.83
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood (2008) 6.39
Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med (2010) 6.26
Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol (2006) 5.00
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol (2005) 4.06
Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity (2009) 3.32
TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - precursors. Am J Transplant (2004) 3.15
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood (2007) 2.91
Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol (2009) 2.87
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2005) 2.83
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol (2009) 2.63
Epigenetic mechanisms of regulation of Foxp3 expression. Blood (2009) 2.27
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood (2010) 2.25
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma (2007) 2.21
Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med (2011) 2.14
The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. Nat Immunol (2007) 2.13
Attendance at cardiac rehabilitation is associated with lower all-cause mortality after 14 years of follow-up. Heart (2012) 2.05
c-Maf regulates IL-10 expression during Th17 polarization. J Immunol (2009) 1.99
Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol (2008) 1.99
Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci U S A (2009) 1.95
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood (2014) 1.95
CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature (2009) 1.94
Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation (2012) 1.93
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood (2013) 1.87
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood (2010) 1.82
Ureteral stents are associated with reduced risk of ureteral complications after kidney transplantation: a large single center experience. Transplantation (2012) 1.79
Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One (2010) 1.77
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma (2014) 1.77
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. Br J Haematol (2007) 1.76
Preparedness of the CTSA's structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS). Clin Transl Sci (2012) 1.76
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood (2011) 1.75
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol (2006) 1.67
Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining. Clin J Am Soc Nephrol (2007) 1.64
Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. J Immunol (2005) 1.64
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. Leuk Lymphoma (2009) 1.59
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years. Leuk Res (2009) 1.57
Immune cell-derived c3 is required for autoimmune diabetes induced by multiple low doses of streptozotocin. Diabetes (2010) 1.57
Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. J Clin Invest (2010) 1.55
Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes (2006) 1.49
Requirements for T lymphocyte migration in explanted lymph nodes. J Immunol (2007) 1.48
Protease inhibitors modulate apoptosis in mesangial cells derived from a mouse model of HIVAN. Kidney Int (2004) 1.46
Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses. J Immunol (2003) 1.45
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood (2002) 1.45
Long-term behavioral outcomes after attendance at a secondary prevention clinic for cardiac patients. J Cardiopulm Rehabil (2003) 1.45
The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia. Cancer (2011) 1.42
IL-6 plays a unique role in initiating c-Maf expression during early stage of CD4 T cell activation. J Immunol (2005) 1.42
CD4+ CD25+ CD62+ T-regulatory cell subset has optimal suppressive and proliferative potential. Am J Transplant (2004) 1.39
Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer (2009) 1.36
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2008) 1.34
Medical risks in living kidney donors: absence of proof is not proof of absence. Clin J Am Soc Nephrol (2006) 1.31
Identification of a distant T-bet enhancer responsive to IL-12/Stat4 and IFNgamma/Stat1 signals. Blood (2007) 1.29
Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol (2007) 1.29
Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. Blood (2012) 1.27
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol (2009) 1.27
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer (2003) 1.26
Committing embryonic stem cells to early endocrine pancreas in vitro. Stem Cells (2004) 1.23
How should we measure and report radiotherapy-induced xerostomia? Semin Radiat Oncol (2003) 1.23
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer (2004) 1.18
Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer (2006) 1.18
FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes. J Clin Invest (2003) 1.18
Advanced pneumatic therapy in self-care of chronic lymphedema of the trunk. Lymphat Res Biol (2010) 1.17
T-bet and eomesodermin play critical roles in directing T cell differentiation to Th1 versus Th17. J Immunol (2008) 1.17
Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant (2004) 1.17
Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol (2007) 1.15
Renal gene and protein expression signatures for prediction of kidney disease progression. Am J Pathol (2009) 1.15
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev (2010) 1.13
Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant (2003) 1.12
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol (2011) 1.12
Regulatory T cell migration during an immune response. Trends Immunol (2012) 1.10
Tubular expression of KIM-1 does not predict delayed function after transplantation. J Am Soc Nephrol (2009) 1.10
Concern The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, Medicare, and Medicaid. Head Neck Oncol (2012) 1.09
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood (2011) 1.09
Adenovirus transduction induces expression of multiple chemokines and chemokine receptors in murine beta cells and pancreatic islets. Am J Transplant (2003) 1.08
Treatment of recurrent focal segmental glomerular sclerosis posttransplant with a multimodal approach including high-galactose diet and oral galactose supplementation. Transplantation (2011) 1.08
The variable pathology of kidney disease after liver transplantation. Transplantation (2010) 1.08
ZnO based thermopower wave sources. Chem Commun (Camb) (2012) 1.08
The kinetics and pattern of tracheal allograft re-epithelialization. Am J Respir Cell Mol Biol (2003) 1.07
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood (2011) 1.07
Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. Clin J Am Soc Nephrol (2008) 1.06
Role of p38 mitogen-activated protein kinase phosphorylation and Fas-Fas ligand interaction in morphine-induced macrophage apoptosis. J Immunol (2002) 1.05
Atomically thin layers of MoS2 via a two step thermal evaporation-exfoliation method. Nanoscale (2011) 1.05
Mechanically Tunable Dielectric Resonator Metasurfaces at Visible Frequencies. ACS Nano (2015) 1.05
Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation. Blood (2009) 1.04